According to a recent Mayo Clinic-led study, most patients with triple-negative breast cancer should undergo genetic testing for mutations in known breast cancer predisposition genes, including BRCA1 and BRCA2. The findings come from the largest analysis to date of genetic mutations in this aggressive form of breast cancer.
Mayo Clinic Study Finds Chromosomal Rearrangements Help Distinguish Between Independent Primary Tumors and Metastasis
A Mayo Clinic study has found a diagnostic test based on chromosomal rearrangements can trace the lineage of lung cancer to determine whether two separate lung cancers in the same patient are independent tumors or a tumor that has spread to another region of the lung. For patients with multiple tumors, that distinction could mean the difference between early stage cancer that may be cured by surgery and incurable late-stage disease.
GenomeDx Biosciences today announced that the company has expanded its research agreement with Mayo Clinic to initiate a validation study to expand the use of the Decipher® Prostate Cancer Classifier, a genomic test capable of predicting metastatic prostate cancer, for use in prostate biopsy specimens.
Mayo Clinic Pathologists Decrease Need for Repeat Surgeries
Cologuard Receives FDA Approval
CAP TODAY: “Unraveling Metastasis With Circulating Tumor Cells”
Mayo Clinic Researchers Discover New Form of Cancer
2014 ASCO Annual Meeting